Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Former Insys Therapeutics Executives Charged in Fentanyl Pushing Scheme



While the opioid drug is only approved for the treatment of cancer pain, the executives are accused of paying doctors to prescribe the drug for other, unapproved indications.

Share this!

December 12, 2016 | by Sarah Hand, M.Sc.

After a year of investigation, six former executives of Insys Therapeutics – including former CEO, Michael Babich – have been arrested on charges of bribing physicians to prescribe the company’s fentanyl-based painkiller, Subsys. While the opioid drug is only approved for the treatment of cancer pain, the executives are accused of paying doctors to prescribe the drug for other, unapproved indications.

In addition to the ex-CEO, the former national director of sales, former VP of sales, former VP of managed markets and two former regional sales directors were all arrested in connection with the bribery scheme. The US Attorney's Office of the District of Massachusetts announced the arrests of the former executives of the Arizona-based Insys last week.

The executives are also accused of conspiring to defraud health insurance providers, who would only pay for the drug when it was prescribed to patients diagnosed with cancer. They overcame this roadblock by allegedly establishing a reimbursement unit, aimed at securing authorization from payers and pharmacy benefit managers before the drugs were prescribed.

“Patient safety is paramount and prescriptions for these highly addictive drugs, especially fentanyl, which is among the most potent and addictive opioids, should be prescribed without the influence of corporate money,” said US Attorney Carmen M. Ortiz. “I hope that today’s charges send a clear message that we will continue to attack the opioid epidemic from all angles, whether it is corporate greed or street level dealing.”

Prescribing opioid drugs is being taken very seriously in the US where the medications are being linked to addiction, overdose and deaths. According to the US Department of Health and Human Services, an average of 650,000 opioid prescriptions are filled every day in the US.

Opioid-related deaths have been on the rise, with the majority of fatalities being linked to abuse of the powerful painkillers. Opioid abuse costs US healthcare and social systems $55 billion, each year.

“We take allegations of paying kickbacks to physicians in exchange for prescribing medically unnecessary painkillers extremely seriously,” said Special Agent in Charge Phillip Coyne of the U.S. Department of Health and Human Services, Office of the Inspector General. “Working closely with our law enforcement partners, we will continue to protect the health of Medicare beneficiaries and the integrity of the nation’s healthcare system.”

Keywords: Opioid, Prescriptions, Payers


Share this with your colleagues!

New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News

Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News

Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


Strategies for Deploying Innovative Solutions for Perimeter Security

Natural History vs. Registry Studies in Rare Disease

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

Copyright © 2016-2017 Honeycomb Worldwide Inc.